Literature DB >> 19605350

Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines.

Larissa M Podust1, Hugues Ouellet, Jens P von Kries, Paul R Ortiz de Montellano.   

Abstract

The Mycobacterium tuberculosis P450 enzymes are of interest for their pharmacological development potential, as evidenced by their susceptibility to inhibition by antifungal azole drugs that normally target sterol 14alpha-demethylase (CYP51). Although antifungal azoles show promise, direct screening of compounds against M. tuberculosis P450 enzymes may identify novel, more potent, and selective inhibitory scaffolds. Here we report that CYP130 from M. tuberculosis has a natural propensity to bind primary arylamines with particular chemical architectures. These compounds were identified via a high throughput screen of CYP130 with a library of synthetic organic molecules. As revealed by subsequent x-ray structure analysis, selected compounds bind in the active site by Fe-coordination and hydrogen bonding of the arylamine group to the carbonyl oxygen of Gly(243). As evidenced by the binding of structural analogs, the primary arylamine group is indispensable, but synergism due to hydrophobic contacts between the rest of the molecule and protein amino acid residues is responsible for a binding affinity comparable with that of the antifungal azole drugs. The topology of the CYP130 active site favors angular coordination of the arylamine group over the orthogonal coordination of azoles. Upon substitution of Gly(243) by an alanine, the binding mode of azoles and some arylamines reverted from type II to type I because of hydrophobic and steric interactions with the alanine side chain. We suggest a role for the conserved Ala(Gly)(243)-Gly(244) motif in the I-helix in modulating both the binding affinity of the axial water ligand and the ligand selectivity of cytochrome P450 enzymes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19605350      PMCID: PMC2757224          DOI: 10.1074/jbc.M109.017632

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  ESPript: analysis of multiple sequence alignments in PostScript.

Authors:  P Gouet; E Courcelle; D I Stuart; F Métoz
Journal:  Bioinformatics       Date:  1999-04       Impact factor: 6.937

2.  In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv.

Authors:  Zahoor Ahmad; Sadhna Sharma; G K Khuller
Journal:  FEMS Microbiol Lett       Date:  2005-10-01       Impact factor: 2.742

3.  Antifungal and antimycobacterial activity of new imidazole and triazole derivatives. A combined experimental and computational approach.

Authors:  Elena Banfi; Giuditta Scialino; Daniele Zampieri; Maria Grazia Mamolo; Luciano Vio; Marco Ferrone; Maurizio Fermeglia; Maria Silvia Paneni; Sabrina Pricl
Journal:  J Antimicrob Chemother       Date:  2006-05-18       Impact factor: 5.790

4.  The potential of azole antifungals against latent/persistent tuberculosis.

Authors:  Zahoor Ahmad; Sadhna Sharma; Gopal K Khuller
Journal:  FEMS Microbiol Lett       Date:  2006-05       Impact factor: 2.742

Review 5.  Functional interaction of nitrogenous organic bases with cytochrome P450: a critical assessment and update of substrate features and predicted key active-site elements steering the access, binding, and orientation of amines.

Authors:  Peter Hlavica
Journal:  Biochim Biophys Acta       Date:  2006-02-10

Review 6.  Cytochrome P450 activation of arylamines and heterocyclic amines.

Authors:  Donghak Kim; F Peter Guengerich
Journal:  Annu Rev Pharmacol Toxicol       Date:  2005       Impact factor: 13.820

7.  Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.

Authors:  Zahoor Ahmad; Sadhna Sharma; G K Khuller
Journal:  FEMS Microbiol Lett       Date:  2006-08       Impact factor: 2.742

8.  Expression, purification and spectroscopic characterization of the cytochrome P450 CYP121 from Mycobacterium tuberculosis.

Authors:  Kirsty J McLean; Myles R Cheesman; Stuart L Rivers; Alison Richmond; David Leys; Stephen K Chapman; Graeme A Reid; Nicholas C Price; Sharon M Kelly; John Clarkson; W Ewen Smith; Andrew W Munro
Journal:  J Inorg Biochem       Date:  2002-09-20       Impact factor: 4.155

9.  Genetic requirements for mycobacterial survival during infection.

Authors:  Christopher M Sassetti; Eric J Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

10.  Mycobacterium tuberculosis Rv1395 is a class III transcriptional regulator of the AraC family involved in cytochrome P450 regulation.

Authors:  Chiara Recchi; Bianca Sclavi; Jean Rauzier; Brigitte Gicquel; Jean-Marc Reyrat
Journal:  J Biol Chem       Date:  2003-06-25       Impact factor: 5.157

View more
  15 in total

1.  The use of small molecule high-throughput screening to identify inhibitors of the proteinase 3-NB1 interaction.

Authors:  M Choi; C Eulenberg; S Rolle; J P von Kries; F C Luft; R Kettritz
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  Multiple ligand docking by Glide: implications for virtual second-site screening.

Authors:  Márton Vass; Ákos Tarcsay; György M Keserű
Journal:  J Comput Aided Mol Des       Date:  2012-05-26       Impact factor: 3.686

3.  Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51).

Authors:  Andrew G S Warrilow; Claire M Martel; Josie E Parker; Nadja Melo; David C Lamb; W David Nes; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

Review 4.  Diversity of P450 enzymes in the biosynthesis of natural products.

Authors:  Larissa M Podust; David H Sherman
Journal:  Nat Prod Rep       Date:  2012-07-23       Impact factor: 13.423

5.  Azole affinity of sterol 14α-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens.

Authors:  Andrew G Warrilow; Josie E Parker; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2012-12-28       Impact factor: 5.191

Review 6.  Potential drug targets in the Mycobacterium tuberculosis cytochrome P450 system.

Authors:  Paul R Ortiz de Montellano
Journal:  J Inorg Biochem       Date:  2018-01-12       Impact factor: 4.155

Review 7.  Interactions of cytochrome P450s with their ligands.

Authors:  Kip P Conner; Caleb M Woods; William M Atkins
Journal:  Arch Biochem Biophys       Date:  2010-10-19       Impact factor: 4.013

8.  Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1.

Authors:  Hugues Ouellet; Petrea M Kells; Paul R Ortiz de Montellano; Larissa M Podust
Journal:  Bioorg Med Chem Lett       Date:  2010-11-05       Impact factor: 2.823

Review 9.  Resistance to antifungals that target CYP51.

Authors:  Josie E Parker; Andrew G S Warrilow; Claire L Price; Jonathan G L Mullins; Diane E Kelly; Steven L Kelly
Journal:  J Chem Biol       Date:  2014-08-27

10.  Catalytic diversity and homotropic allostery of two Cytochrome P450 monooxygenase like proteins from Trichoderma brevicompactum.

Authors:  Razak Hussain; Indu Kumari; Shikha Sharma; Mushtaq Ahmed; Tabreiz Ahmad Khan; Yusuf Akhter
Journal:  J Biol Inorg Chem       Date:  2017-10-10       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.